MedPath
Found 38 clinical trials|View Analysis
Sort by:

Mezigdomide, Carfilzomib, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma in Patients With Extramedullary Disease

Phase 2
Not yet recruiting
Conditions
Extramedullary Disease in Multiple Myeloma
Recurrent Multiple Myeloma
Refractory Multiple Myeloma
Interventions
Biological: Mezigdomide
Drug: Carfilzomib
Drug: Dexamethasone
Procedure: Echocardiography
Procedure: Positron Emission Tomography
Procedure: Computed Tomography
Procedure: Computed Tomography Assisted Biopsy
Procedure: Bone Marrow Aspiration
Procedure: Bone Marrow Biopsy
Procedure: Biospecimen Collection
First Posted Date
2024-10-04
Last Posted Date
2024-12-04
Lead Sponsor
Roswell Park Cancer Institute
Target Recruit Count
28
Registration Number
NCT06627751

SX-682 in Combination With Carfilzomib, Daratumumab-Hyaluronidase, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

Phase 1
Not yet recruiting
Conditions
Recurrent Multiple Myeloma
Refractory Multiple Myeloma
Interventions
Drug: Cxcr1/2 Inhibitor SX-682
Drug: Daratumumab and Recombinant Human Hyaluronidase
Drug: Carfilzomib
Drug: Dexamethasone
Procedure: Biospecimen Collection
Procedure: Bone Marrow Aspiration
Procedure: Echocardiography
Procedure: Positron Emission Tomography
Procedure: Computed Tomography
Procedure: Magnetic Resonance Imaging
First Posted Date
2024-10-01
Last Posted Date
2024-12-04
Lead Sponsor
Roswell Park Cancer Institute
Target Recruit Count
15
Registration Number
NCT06622005

ST-067 and Teclistamab for the Treatment of Relapsed or Refractory Multiple Myeloma

Phase 1
Recruiting
Conditions
Recurrent Multiple Myeloma
Refractory Multiple Myeloma
Interventions
Biological: Vevoctadekin
Procedure: Bone Marrow Aspiration
Procedure: Bone Marrow Biopsy
Other: Medical Chart Review
Drug: Teclistamab
Procedure: Biospecimen Collection
First Posted Date
2024-09-19
Last Posted Date
2024-12-30
Lead Sponsor
University of Washington
Target Recruit Count
20
Registration Number
NCT06588660
Locations
🇺🇸

Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Clinical Study of CD38\CS1 Chimeric Antigen Receptor T Cells in the Treatment of Refractory/Recurrent Multiple Myeloma

Early Phase 1
Active, not recruiting
Conditions
ORR,OS,PFS
Interventions
Biological: CD38/CS1 injection
First Posted Date
2024-08-28
Last Posted Date
2024-08-28
Lead Sponsor
The Second Hospital of Shandong University
Target Recruit Count
10
Registration Number
NCT06574958
Locations
🇨🇳

Second Hospital of Shandong University, Shandong, Shandong, China

A Study of QLS4131 in Patients With Recurrent or Refractory Multiple Myeloma

Phase 1
Not yet recruiting
Conditions
Relapsed or Refractory Multiple Myeloma
Interventions
Drug: QLS4131 Injection
First Posted Date
2024-07-15
Last Posted Date
2024-07-15
Lead Sponsor
Qilu Pharmaceutical Co., Ltd.
Target Recruit Count
90
Registration Number
NCT06500507
Locations
🇨🇳

Institute of Hematology & Blood Diseases Hospital, Tianjin, Tianjin, China

Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma

Phase 1
Recruiting
Conditions
Recurrent Multiple Myeloma
Refractory Multiple Myeloma
Interventions
Procedure: Biospecimen Collection
Procedure: Bone Marrow Aspiration
Procedure: Bone Marrow Biopsy
Procedure: Computed Tomography
Drug: Iberdomide
Procedure: Magnetic Resonance Imaging
Procedure: Positron Emission Tomography
Drug: Teclistamab
First Posted Date
2024-06-18
Last Posted Date
2024-12-03
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
26
Registration Number
NCT06465316
Locations
🇺🇸

Virginia Commonwealth University/Massey Cancer Center, Richmond, Virginia, United States

An Clinical Study of NKG2D-CAR-NK Cells for the Treatment of Refractory Recurrent Multiple Myeloma

Early Phase 1
Not yet recruiting
Conditions
Multiple Myeloma
Interventions
Drug: NKG2D Chimeric Antigen Receptor NK Cell Injection
First Posted Date
2024-04-23
Last Posted Date
2024-04-23
Lead Sponsor
Changzhou No.2 People's Hospital
Target Recruit Count
9
Registration Number
NCT06379451
Locations
🇨🇳

Changzhou Second People's Hospital, Changzhou, Jiangsu, China

Testing the Combination of Two Approved Drugs and One Experimental Drug in Patients With Relapsed or Refractory Multiple Myeloma

Phase 1
Not yet recruiting
Conditions
Recurrent Multiple Myeloma
Refractory Multiple Myeloma
Interventions
Drug: Iberdomide
Biological: Belantamab Mafodotin
Drug: Dexamethasone
Procedure: Echocardiography
Procedure: Computed Tomography
Procedure: Magnetic Resonance Imaging
Procedure: Positron Emission Tomography
Procedure: Bone Marrow Biopsy
Procedure: Bone Marrow Aspiration
Procedure: Biospecimen Collection
First Posted Date
2024-01-30
Last Posted Date
2025-01-03
Lead Sponsor
Alliance for Clinical Trials in Oncology
Target Recruit Count
88
Registration Number
NCT06232044
Locations
🇺🇸

Mary Greeley Medical Center, Ames, Iowa, United States

🇺🇸

McFarland Clinic - Ames, Ames, Iowa, United States

🇺🇸

McFarland Clinic - Boone, Boone, Iowa, United States

and more 9 locations

Donor Immune Cells (TGFbi NK Cells) and Isatuximab for the Treatment of Relapsed or Refractory Multiple Myeloma

Phase 1
Recruiting
Conditions
Refractory Multiple Myeloma
Recurrent Multiple Myeloma
Interventions
Procedure: Biospecimen Collection
Procedure: Bone Marrow Aspiration and Biopsy
Drug: Cyclophosphamide
Drug: Dexamethasone
Procedure: Echocardiography
Biological: Isatuximab
Other: Questionnaire Administration
Biological: Universal Donor Expanded TGF-beta-imprinted NK Cells
First Posted Date
2024-01-12
Last Posted Date
2024-05-30
Lead Sponsor
Elvira Umyarova
Target Recruit Count
30
Registration Number
NCT06203912
Locations
🇺🇸

Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

Elotuzumab, CC-92480, and Dexamethasone for the Treatment of Relapsed or Refractory Myeloma After CD38- and BCMA-Targeted Therapies

Phase 1
Recruiting
Conditions
Recurrent Multiple Myeloma
Refractory Multiple Myeloma
Interventions
Procedure: Biospecimen Collection
Procedure: Bone Marrow Aspiration
Procedure: Bone Marrow Biopsy
Procedure: Computed Tomography
Drug: Dexamethasone
Procedure: Echocardiography
Biological: Elotuzumab
Procedure: Magnetic Resonance Imaging
Biological: Mezigdomide
Procedure: X-Ray Imaging
First Posted Date
2023-08-08
Last Posted Date
2024-03-18
Lead Sponsor
Abdullah Khan
Target Recruit Count
27
Registration Number
NCT05981209
Locations
🇺🇸

Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

© Copyright 2025. All Rights Reserved by MedPath